Kelun

Sichuan Kelun Pharmaceutical Co., Ltd. successfully listed on the Shenzhen Stock Exchange in June 2010, immediately launching a 10-billion-yuan industrial investment plan and beginning to implement the "three-engine drive, innovation-led growth" development strategy. The first engine is to maintain Kelun's leading position in the infusion field through continuous industrial upgrading and product portfolio adjustment; the second engine is to build an antibiotic competitive advantage from intermediates, active pharmaceutical ingredients to formulations by innovatively developing and utilizing high-quality natural resources; the third engine is to accumulate the ultimate driving force for long-term corporate success through the construction of a research and development system and diversified technological innovation. In the infusion sector, Kelun has achieved comprehensive industrial upgrading, possessing profitability characterized by both advanced manufacturing and new materials, occupying the strategic high ground of technological innovation and quality benchmarks. Kelun has established a closed-loop responsibility system covering drug research and development, production, logistics transfer, and end-user application to ensure product quality and safety. Its leading products have been exported in bulk and are highly regarded in more than 50 countries and regions. Kelun's self-developed Colibag® is a pioneering innovation both domestically and internationally, with over 20 patents, winning the National Science and Technology Progress Award. It offers higher safety and cost-effectiveness compared to traditional infusion products and holds significant application value in reducing energy consumption and environmental protection, representing the direction of China’s infusion product development. In the antibiotics field, the company moved westward, establishing Yili Chuan Ning Biotechnology Co., Ltd. to produce thiocyanate erythromycin and cephalosporin series intermediates. Through R&D trials, upgrades, innovative collaborations, and the introduction of advanced domestic and international technology equipment, Chuan Ning was approved to construct the National Environmental Protection Engineering Technology Center for Harmless Treatment and Resource Utilization of Antibiotic Mycelial Waste, addressing fundamental issues in the antibiotic industry. In December 2022, Chuan Ning Biotech successfully listed on the ChiNext Board of the Shenzhen Stock Exchange, fully advancing into the synthetic biology field. Since its establishment, Kelun has invested over 10 billion yuan in R&D innovation, establishing the "National Enterprise Technology Center," "National Large-Volume Injection Engineering Technology Research Center," and the "National-Local Joint Engineering Laboratory for Large-Volume Injection." In 2022, Kelun Biotech was approved by the National Development and Reform Commission to establish the only nationally laid-out "National Engineering Research Center for Biologically Targeted Drugs." To date, Kelun has filed over 1,500 patent applications and obtained more than 500 authorized invention patents, initiating the development of over 400 major drugs across multiple disease areas such as oncology, bacterial infections, and parenteral nutrition. Since 2017, more than 20 drugs have been approved annually for market launch, making Kelun a leading player in China’s generic drug industry with a bid-winning rate exceeding 90% in national centralized drug procurement. Meanwhile, nearly 20 Class 1 innovative drugs have entered clinical research or production application stages, with over ten innovative projects and patents licensed overseas to developed markets like Europe and the United States, entering a virtuous cycle of R&D investment and output. Kelun Biotech has successfully built an internationally renowned ADC R&D platform. In 2022, it reached three major licensing agreements with multinational giant Merck, totaling nearly $11.8 billion, ranking first in the history of international licensing transactions in China's pharmaceutical industry and topping the 2022 Global Pharmaceutical Industry Licensing Transaction Cooperation list, firmly establishing Kelun's position in the forefront of China’s innovative drug R&D sector. In July 2023, Kelun Biotech successfully listed on the Hong Kong Stock Exchange, marking the start of a new journey for Kelun's innovative R&D and global layout. Adhering to the corporate mission of "pursuing truth in science and goodness in ethics," Kelun has donated over 300 million yuan to public welfare, social causes, and charity, demonstrating its values and sense of social justice, showcasing an excellent private enterprise’s healthy development image under market economy conditions.